- Home
- XXII vs TNFA Comparison
XXII vs TNFA Comparison
Compare XXII & TNFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- TNFA
- Stock Information
- Founded
- XXII 1998
- TNFA 2014
- Country
- XXII United States
- TNFA United States
- Employees
- XXII N/A
- TNFA N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- TNFA
- Sector
- XXII Health Care
- TNFA
- Exchange
- XXII Nasdaq
- TNFA NYSE
- Market Cap
- XXII 2.8M
- TNFA 3.2M
- IPO Year
- XXII N/A
- TNFA N/A
- Fundamental
- Price
- XXII $3.95
- TNFA $0.70
- Analyst Decision
- XXII
- TNFA
- Analyst Count
- XXII 0
- TNFA 0
- Target Price
- XXII N/A
- TNFA N/A
- AVG Volume (30 Days)
- XXII 2.6M
- TNFA 435.7K
- Earning Date
- XXII 03-27-2025
- TNFA 03-31-2025
- Dividend Yield
- XXII N/A
- TNFA N/A
- EPS Growth
- XXII N/A
- TNFA N/A
- EPS
- XXII N/A
- TNFA N/A
- Revenue
- XXII $17,304,000.00
- TNFA N/A
- Revenue This Year
- XXII $56.94
- TNFA N/A
- Revenue Next Year
- XXII $2.98
- TNFA N/A
- P/E Ratio
- XXII N/A
- TNFA N/A
- Revenue Growth
- XXII N/A
- TNFA N/A
- 52 Week Low
- XXII $3.80
- TNFA $0.64
- 52 Week High
- XXII $581.85
- TNFA $4.50
- Technical
- Relative Strength Index (RSI)
- XXII 37.42
- TNFA 28.03
- Support Level
- XXII $4.80
- TNFA $0.81
- Resistance Level
- XXII $12.49
- TNFA $1.38
- Average True Range (ATR)
- XXII 1.08
- TNFA 0.14
- MACD
- XXII 0.02
- TNFA -0.05
- Stochastic Oscillator
- XXII 3.50
- TNFA 3.25
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About TNFA TNF PHARMACEUTICALS INC EFFEC
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.